Login
$ACRS
$3.66 +$0.05 (1.52%) After hours

$ACRS 8-K/A SEC Filings

Filed On Filing
05 Feb 2024 8-K/A: Departure/Election of Directors or Officers; Compensation

(b)Departure of Douglas Manion as Chief Executive Officer and President and Director

18 Jan 2019 8-K/A: Financial Statements and Exhibits

These unaudited pro forma condensed combined financial statements of Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) are presented to illustrate the estimated effects of the acquisition of RHOFADE (oxymetazoline hydrochloride) cr...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support